Free Trial
NASDAQ:ENGN

enGene Q3 2025 Earnings Report

enGene logo
$8.39 -0.50 (-5.62%)
Closing price 10/10/2025 04:00 PM Eastern
Extended Trading
$8.36 -0.04 (-0.42%)
As of 10/10/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

enGene EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

enGene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

enGene Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, September 11, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

enGene's Q4 2025 earnings is scheduled for Friday, December 19, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

enGene Earnings Headlines

Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.tc pixel
How to change the default search engine on your computer or phone
How to make Google your default search engine on any major web browser
See More enGene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email.

About enGene

enGene (NASDAQ:ENGN), Inc. is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages. Each EDV is surface‐decorated with bispecific antibodies designed to bind specific tumor antigens, enabling selective accumulation in malignant tissues. The platform supports a range of payloads—from chemotherapeutic agents to nucleic acid–based molecules—providing versatility in addressing diverse tumor profiles.

Headquartered in San Diego, California, enGene collaborates with leading academic and research institutions to propel its pipeline forward. The company is overseen by a management team with deep expertise in gene and cell therapy development, drug delivery systems, and oncology research, positioning enGene to tackle the complex challenges inherent in targeted cancer therapy.

View enGene Profile

More Earnings Resources from MarketBeat